The FDA targets pharma’s grip on costly, toxic cancer drug dosages
The FDA told Amgen to test whether a quarter-dose of a lung cancer drug worked as well as Amgen’s recommended amount. It did, with fewer side effects. But cutting the dose means less revenue.